"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
Descriptor ID |
D011719
|
MeSH Number(s) |
D03.383.679
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
1999 | 2 | 0 | 2 |
2001 | 1 | 0 | 1 |
2002 | 2 | 2 | 4 |
2003 | 5 | 5 | 10 |
2004 | 13 | 2 | 15 |
2005 | 14 | 4 | 18 |
2006 | 15 | 9 | 24 |
2007 | 8 | 10 | 18 |
2008 | 6 | 6 | 12 |
2009 | 8 | 5 | 13 |
2010 | 8 | 8 | 16 |
2011 | 10 | 15 | 25 |
2012 | 8 | 13 | 21 |
2013 | 4 | 16 | 20 |
2014 | 6 | 16 | 22 |
2015 | 6 | 7 | 13 |
2016 | 3 | 1 | 4 |
2017 | 2 | 4 | 6 |
2018 | 1 | 1 | 2 |
2019 | 4 | 3 | 7 |
2020 | 4 | 5 | 9 |
2021 | 10 | 5 | 15 |
2022 | 1 | 5 | 6 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center. Leuk Lymphoma. 2023 05; 64(5):1050-1053.
-
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nat Commun. 2022 09 14; 13(1):5401.
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
-
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022 06 01; 107(6):1335-1346.
-
Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP. Eur J Med Chem. 2022 Jul 05; 237:114407.
-
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022 03 01; 97(3):322-328.
-
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na?ve chronic lymphocytic leukemia. Leukemia. 2022 04; 36(4):1171-1175.
-
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv. 2021 12 14; 5(23):5215-5219.
-
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol. 2021 Dec; 8(12):e912-e921.
-
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.